Loading…

CryoPort, Inc.CYRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Air Freight/Couriers
Momentum leader 94
Mkt cap
$1.02B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$23.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-21.1 pp
WACC 12.9%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$20.17
1D+2.2%
1W-1.9%
1M+15.7%
3M+20.7%
6M+43.4%
YTD+110.1%
1Y+137.0%
ATR %5.1%
Beta1.58
52w lowhigh7.4% off high

What CryoPort does

Employees: 738

CryoPort at a glance

Size CryoPort (CYRX) is a United States Health Care company (Air Freight/Couriers) with a market value of $1.02B, the 2219th largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.17 on 18 Nov 2026.

Performance Over six months the shares gained 43.4%, against +7.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 1.1% over the last twelve months (peer median +10.4%); the operating margin is -20.0% (peer median -5.2%).

Valuation It trades at 4.7× enterprise value to sales against a peer median of 4.5× (6th most expensive of 13).

Capital Return on invested capital runs 21.1 points below its cost of capital (12.9% WACC).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026CYRX 142Peer median 107
Six months, rebased to 100: CryoPort against the median of its 20 peers (local-currency closes).

CryoPort financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$192M$176M$157M$233M$237M
Revenue growth—+12%-33%-2%—
Gross profit$77.3M$70.4M$57.1M$83.0M$88.8M
EBITDA-$12.7M-$16.8M-$35.5M-$31.2M-$6.97M
Net income-$37.1M-$38.7M-$115M-$99.6M-$37.3M
Free cash flow-$18.8M-$25.0M-$33.6M-$39.5M-$24.0M
Capital expenditure$30.9M$19.5M$21.3M$44.9M$24.2M
Total debt$232M$231M$243M$416M$436M

Quarterly statements and history in the cockpit →

CryoPort competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%INBXCSTLANROAHCOSVRACBLLIRMDSGPSIBNSPTXJBIOIARTOMERATECDRTSMLTXIMTXGDRXCYRX6-month return →1-month return →
Up and to the right = strong over both horizons. CryoPort is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×200×400×INBXCSTLAHCOCBLLIRMDIARTIMTXCYRXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CryoPort is the large dot.

CryoPort competitors and peer comparison

How CryoPort compares with its peers

Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CryoPort against its 20 peers (data as of 18 Nov 2026)
MeasureCYRXPeer medianRank in peer set
1-month return+15.7%-4.8%2nd highest of 21
6-month return+43.4%+7.4%3rd highest of 20
Distance from 52-week high-7.4%-31.9%highest of 21
Revenue growth (TTM)+1.1%+10.4%5th lowest of 11
Operating margin-20.0%-5.2%5th lowest of 13
EV / Sales4.7×4.5×6th most expensive of 13
ROIC minus cost of capital-21.1 pp-8.4 pp4th lowest of 11

Peer table

Peer set: Sector in the same market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CryoPort CYRXUnited States$1.02B+43%+1%-20%4.7×n/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%2.1×57.7%+40.6%
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
AdaptHealth AHCOUnited States$1.01B-30%-3%3%0.9×16.8%+25.2%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Ceribell CBLLUnited States$995M+42%+31%-70%8.3×n/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%11.1×18.5%+21.5%
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%4.3×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%
Omeros OMERUnited States$1.08B+24%n/a-56%17.3×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%1.9×n/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
GoodRx GDRXUnited States$1.15B+33%-2%12%1.8×6.3%+7.7%

Questions

Which companies are CryoPort's closest peers?
The cockpit's peer set: Inhibrx Biosciences (INBX), Castle Biosciences (CSTL), Alto Neuroscience (ANRO), AdaptHealth (AHCO), Savara (SVRA), Ceribell (CBLL), IRadimed (IRMD), SpyGlass Pharma (SGP).
Is CryoPort expensive compared with its peers?
On ev / sales it trades at 4.7× against a peer median of 4.5×, 6th most expensive of 13 in its peer set.
How has CryoPort stock performed?
Over six months to 18 Nov 2026 the shares returned +43.4% against +7.4% for the median peer; over one year +137.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.